April 3, 2018 / 5:07 AM / 8 months ago

BRIEF-‍EMA To Review Dupixent As Potential Treatment For Inadequately Controlled Moderate-To Severe Asthma​

1 Min Read

April 3 (Reuters) - Regeneron Pharmaceuticals Inc:

* ‍EMA TO REVIEW DUPIXENT® (DUPILUMAB) AS POTENTIAL TREATMENT FOR INADEQUATELY CONTROLLED MODERATE-TO-SEVERE ASTHMA​

* ‍EUROPEAN MEDICINES AGENCY (EMA) HAS ACCEPTED FOR REVIEW AN APPLICATION FOR DUPIXENT​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.

© 2018 Reuters. All Rights Reserved.